Anti-Rheumatic Rx

      RT @RichardPAConway: Another benefit of DMARD use in RA. Dr Sood reports lower risk of long term opioid use. Very import

      Richard Conway RichardPAConway

      3 years 10 months ago
      Another benefit of DMARD use in RA. Dr Sood reports lower risk of long term opioid use. Very important given the harm of opioids Abstr#587 #ACR21 @RheumNow https://t.co/d1Dharf5jZ
      RT @ericdeinmd: #ACR21 Abs#0825
      Early RA -Rx-naive: 48 wk, csDMARD+GC vs. 3 bDMARD+MTX (CZP/ABA/TCZ)
      ⭐️Superiority f

      Eric Dein ericdeinmd

      3 years 10 months ago
      #ACR21 Abs#0825 Early RA -Rx-naive: 48 wk, csDMARD+GC vs. 3 bDMARD+MTX (CZP/ABA/TCZ) ⭐️Superiority for ABA+MTX and CZP+MTX vs. to csDMARD+GC, not in TCZ+MTX ⭐️ Radiographic progression low in all ▶️ Short study w very aggressive 1st line combo Rx https://t.co/TJPZkqmN8z @Rheumnow
      RT @RichardPAConway: Dr Exarchou presents incidence of PsA in Sweden. 22/100000. 75% received DMARDs within 2 years, whi

      Richard Conway RichardPAConway

      3 years 10 months ago
      Dr Exarchou presents incidence of PsA in Sweden. 22/100000. 75% received DMARDs within 2 years, which seems high, so perhaps this is tip of iceberg with milder cases undiagnosed. Abstr#0571 #ACR21 @RheumNow https://t.co/kANG6KBnOd
      RT @drdavidliew: For rheumatologists, instinct says in RA everything’s better with MTX. For tofacitinib, where immunog

      David Liew drdavidliew

      3 years 10 months ago
      For rheumatologists, instinct says in RA everything’s better with MTX. For tofacitinib, where immunogenicity not an issue, is that actually true? Canadian registry data: maybe no after 36m, low no. ?valid, markups mine Need to see more of this! #ACR21 ABST0827 ⁦@RheumNow⁩ https://t.co/VVwd4SZgVx
      RT @AurelieRheumo: MTX and liver: FibroScan scores compatible with liver fibrosis are significantly correlated w/ severa

      Aurelie Najm AurelieRheumo

      3 years 10 months ago
      MTX and liver: FibroScan scores compatible with liver fibrosis are significantly correlated w/ several parameters -BMI -waist circumference -male gender -age but NOT MTX cumulative dose in a cohort of 500+ patients. #Abst0786 @RheumNow #ACR21 https://t.co/RkSpVqN4qF https://t.co/9TENaR0WZ3
      RT @KDAO2011: Dr. R Thomas: current studies on prevention of RA:
      👉oral DMARDS (MTX, HCQ)
      👉biologics (RTX, abatace

      TheDaoIndex KDAO2011

      3 years 10 months ago
      Dr. R Thomas: current studies on prevention of RA: 👉oral DMARDS (MTX, HCQ) 👉biologics (RTX, abatacept) 👉 studies regulating T cells to restore tolerance 👉biomarkers of tolerant state & look at people who don't develop RA 👉 imaging as window of subclin dz. #ACR21 @rheumnow https://t.co/5bsu5459az
      RT @ericdeinmd: #ACR21 Abst#0786. Fibroscan screening for liver injury in pts on MTX:
      ▶️No significant correlation b

      Eric Dein ericdeinmd

      3 years 10 months ago
      #ACR21 Abst#0786. Fibroscan screening for liver injury in pts on MTX: ▶️No significant correlation between cumulative MTX dose and liver stiffness by fibroscan, even at high dose MTX. ⭐️Age, sex, waist circumference, BMI are risks @Rheumnow https://t.co/IhcNr9fhEh https://t.co/c7TUoGrNZ7
      ACR21 Daily Recap Day 1
      3 years 10 months ago
      RT @Janetbirdope: Blurred line btwn RA, preRA & RA prevention which makes interpretation of RCTs problematic. I’ve

      Janet Pope Janetbirdope

      3 years 10 months ago
      Blurred line btwn RA, preRA & RA prevention which makes interpretation of RCTs problematic. I’ve learned that if pt has RA not meeting criteria, some Rx ⬇️chance of RA over time-MTX, now #Abatacept but was it RA anyway AND what happens when you stop Rx? #ACR21 @RheumNow abst#0505 https://t.co/HwivsITvCQ
      RT @Yuz6Yusof: #ACR21 #Abstr0261 In stable Non sJIA, is it safe to taper or stop MTX? Of 375 pts in CARRA registry, 24%

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 years 10 months ago
      #ACR21 #Abstr0261 In stable Non sJIA, is it safe to taper or stop MTX? Of 375 pts in CARRA registry, 24% tapered and 14% stopped MTX. No diff in flare rates btw those continued vs tapered/stopped. Sustained remission was in ⬆️tapered vs stopped @RheumNow https://t.co/Mm1yfzRBQz https://t.co/rkHvXWj2oO
      acr_session2.jpeg
      Opening Day Report
      3 years 10 months ago
      The opening of ACR2 Convergence was a hit for all who signed up and viewed in. The day included the presidential address by outgoing president Dr. David Karp (UT Southwestern) and a keynote talk and interview with Dr. Seema Yasmin (Stanford). The Year in Review featured a clinical vs basic science Brigham and Women’s Hospital faceoff between its two faculty, Dr. Karen Costenbader and Dr. Michael Brenner.
      RT @KDAO2011: #GreatDebate: add belimumab (BLMB) vs. voclosporin (VCS) to MMF for lupus nephritis (LN)
      Dr. Petri argues

      TheDaoIndex KDAO2011

      3 years 10 months ago
      #GreatDebate: add belimumab (BLMB) vs. voclosporin (VCS) to MMF for lupus nephritis (LN) Dr. Petri argues for BLMB b/c: (1/2) 👉improvement in LN 👉improvement in non-renal lupus 👉decrease lupus renal mortality 👉**prevent GFR reduction ** 👉long term efficacy #ACR21 @rheumnow
      RT @KDAO2011: Dr B Bermas noted AAP guidelines say avoid MTX while breastfeeding, but the literature show very little MT

      TheDaoIndex KDAO2011

      3 years 10 months ago
      Dr B Bermas noted AAP guidelines say avoid MTX while breastfeeding, but the literature show very little MTX crosses breast milk. Dr Sammaritano stated that is true, but we don’t know how much MTX accumulates,though. #acr21 @rheumnow @UTSWRheum https://t.co/9I7HszorEO
      RT @KDAO2011: Would you allow a pt to continue MTX while breastfeeding? #acr21 @rheumnow

      TheDaoIndex KDAO2011

      3 years 10 months ago
      Would you allow a pt to continue MTX while breastfeeding? #acr21 @rheumnow
      RT @MithuRheum: #ACR21 The Great Debate: Belimumab vs Voclosporin as Add-On Therapy in #LupusNephritis | Dr. Petri &

      Mithu Maheswaranathan, MD MithuRheum

      3 years 10 months ago
      #ACR21 The Great Debate: Belimumab vs Voclosporin as Add-On Therapy in #LupusNephritis | Dr. Petri & Dr. Rovin Audience Vote 🗳: What would you add to mycophenolate first? Belimumab 71%, Voclosporin 29% #ACRAmbassador @ACRheum Summary of Pros & Cons of Each⬇️ https://t.co/OtLxs8IYr9
      How well do you know this week's rheumatology news?
      Take the rheumIQ quiz
      Take the RheumIQ Quiz

      Catch up on Conference Podcasts

      ×